drugset / Trial / NCT04312555

Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Critical Limb Ischemia.

NCT04312555

Phase 4 Unknown 30 enrolled Assiut University
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to assess the efficacy of Alprostadil (Prostaglandin E2) as adjuvant therapy after failure of direct but indirect angiosomal revascularization in patients with critical limb ischemia.

Timeline

Start
2020-04-01
Primary completion
2021-04-01
Completion
2021-10-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprostadil Unknown 0.5 mg Intravenous

Indications